Evotec Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Evotec hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.02%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.02%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Sep 20

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Aug 25

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Aug 10

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Jul 06

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von EVO in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von EVO gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Evotec Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von EVO im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (EVO)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Life Sciences)	0.5%
Analystenprognose (EVO) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von EVO im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von EVO im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von EVO, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da EVO keine Ausschüttungen gemeldet hat.

Evotec Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Evotec: Weak Performance, But Long-Term Potential Is There

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec: Still A Speculative Buy After A Significant Decline

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Evotec SE Announces CEO Transition

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec SE Revises Revenue Guidance for the Full Year 2022

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Evotec SE Confirms Revenue Guidance for 2022

Evotec Se Provides Revenue Guidance for 2022

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

Evotec SE Launches 'beLAB1407' to Accelerate Translational Research from the UK's Academic Life Science Ecosystem in Collaboration with Bristol Myers Squibb

Evotec SE Provides Earnings Guidance for the Year 2021

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership

Evotec SE Enters into Multi-Year Partnership with the Medical Center Hamburg-Eppendorf

Evotec Appoints Cord Dohrmann to the German Council of Science and Humanities

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation

Evotec SE to Report Q3, 2021 Results on Nov 11, 2021

Evotec SE Receives USD 6 Million Payment from Bristol Myers Squibb Company

Evotec SE Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform

Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology Target

Evotec SE announced that it expects to receive €249.999996 million in funding from Mubadala Investment Company PJSC, Novo Holdings A/S

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen